Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer LONDON, December 03, 2024--(BUSINESS WIRE)--Epsilogen ...

Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer Epsilogen, the global leader in the development of ...

NEW YORK – Epsilogen on Tuesday said it began a Phase Ib trial of its investigational therapeutic antibody MOv18 IgE in patients with FRα-expressing, platinum-resistant ovarian cancer. In the trial, ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with ...

IgE is an antibody that plays a key role in allergic responses. It can sometimes also be elevated for other reasons, such as chronic infections or inflammatory diseases. When your IgE levels are high, ...

The antibody – called MOv18 IgE – targets folate receptor alpha which is particularly overexpressed on ovarian tumour cells. The drug is a CRUK-sponsored phase 1 trial due to report results at ...